Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.25.

A number of brokerages have recently commented on CRVS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, October 8th. Mizuho set a $13.00 target price on Corvus Pharmaceuticals in a research report on Wednesday, October 29th. Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Barclays assumed coverage on Corvus Pharmaceuticals in a research note on Monday, October 13th. They issued an “overweight” rating and a $16.00 price target for the company.

Institutional Trading of Corvus Pharmaceuticals

Large investors have recently modified their holdings of the stock. Jump Financial LLC bought a new stake in shares of Corvus Pharmaceuticals during the first quarter worth about $143,000. American Century Companies Inc. boosted its stake in Corvus Pharmaceuticals by 103.9% during the 1st quarter. American Century Companies Inc. now owns 89,265 shares of the company’s stock valued at $284,000 after purchasing an additional 45,491 shares during the last quarter. BML Capital Management LLC bought a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $475,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Corvus Pharmaceuticals during the 2nd quarter worth approximately $672,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Corvus Pharmaceuticals in the first quarter worth approximately $333,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS opened at $8.51 on Tuesday. Corvus Pharmaceuticals has a 52-week low of $2.54 and a 52-week high of $9.32. The firm has a market cap of $635.53 million, a price-to-earnings ratio of -16.06 and a beta of 0.64. The business’s fifty day moving average is $7.72 and its 200-day moving average is $5.68.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, research analysts forecast that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.